glaucoma Avellino Labs Begins Commercial Push for Expanded Ophthalmology Genetic Test Panel Premium The company has launched an updated test called AvaGen that returns diagnostic subtype results for corneal dystrophies and polygenic risk scores for keratoconus. Combination of Sequencing, EHR Data Links Genes to Range of Conditions The exome-by-phenome-wide analysis uncovered 21 novel gene-phenotype associations, including genes linked to glaucoma and diabetes. Glaucoma Protective Variants Uncovered in Genetic Data From UK, Finland With UK Biobank and FinnGenn data, researchers tracked down rare changes in the angiopoietin-like 7 gene that coincide with lower glaucoma and intraocular pressure risk. Glaucoma Polygenic Risk Score Emerges From Multi-Trait Analysis in UK Biobank Participants The new PRS could help identify people at increased risk who may benefit from earlier screening and treatment to prevent blindness. Glaucoma Diagnostic Targeted by Mannin Research, McMaster University Collaboration The test will be designed to detect a protein biomarker in aqueous humor that can be used to determine the severity of glaucoma and to make treatment decisions. May 21, 2018 Glaucoma Risk Factor Linked to More Than 100 Genetic Loci in Europeans Feb 8, 2018 Q Biomed Options Glaucoma Biomarker From WUSTL Oct 2, 2017 CRISPR Editing in Mice Disrupts Glaucoma-Causing Gene Mutation Jan 11, 2016 Through GWAS Meta-Analysis, Researchers Link Three Genes to Glaucoma Sep 10, 2015 Two Risk Genes Interact to Cause Primary Open-Angle Glaucoma Jun 26, 2014 Quark Begins Enrollment in Glaucoma Drug Trial Premium Oct 31, 2013 Sylentis Sees Phase III Trial for Glaucoma Drug by 2015 Premium Oct 15, 2013 UCSD-led Glaucoma Genes Study Lands $6.4M Apr 18, 2013 NIH Awards Nearly $2M in microRNA Research Grants Premium Jul 5, 2012 Sylentis Preps to Move Glaucoma Drug into Phase II Next Year Premium May 3, 2012 Quark to Run Phase IIa Trial of RNAi Drug in Glaucoma Premium Feb 9, 2012 Quark Still Sees IPO as a Possibility as Phase II Trials Near Completion Premium Jan 12, 2012 Quark Releases Positive Phase I Data on Ocular Neuroprotectant Premium Nov 17, 2011 Sylentis Picks up Option to Alnylam RNAi IP Premium Sep 13, 2010 Decode-Led GWAS Uncovers Glaucoma Risk Variant Jul 8, 2010 Sylentis Concludes Phase Ia Study of Glaucoma Drug Premium Apr 1, 2010 Sylentis Eyes Second Part of Phase I/II Trial for Glaucoma Rx, Searches for Partners Premium Mar 4, 2010 Quark Begins Patient Dosing in Phase I Study of Ocular Neuroprotectant Premium Dec 3, 2009 Quark Aims for Five Clinical Indications, New IND in 2010 Premium Aug 20, 2009 Sylentis Aims to Begin Phase I Study of Glaucoma Drug in September Premium Load More Breaking News Canadian Healthcare Providers, Policymakers Value Different Aspects of Clinical Genomic Sequencing New Products Posted to GenomeWeb: Oxford Nanopore, Bio-Rad, NanoString, More People in the News at OraSure, Element Biosciences, Micronoma, More Guardant Health Files Motions to Dismiss, Change Venue in Illumina Patent Lawsuit In Brief This Week: SQI Diagnostics, T2 Biosystems, Enhanc3D, QuidelOrtho, More Illumina, Precision Health Research Singapore Partner for 100K Genomes Population Study The Scan Blend of Omicron With Delta The Associated Press reports that currently circulating Omicron variants have some features previously seen in the Delta variant. Limited Contrast The New York Times reports that there is a shortage of a contrast agent used for some medical scans. Pig Improvement Farmers in China are using genetics to improve their hog herds, according to Reuters. Science Papers Present Way to Molecularly Classify Prostate Cancer, Saliva-Based SARS-CoV-2 Test, More In Science this week: approach to molecularly classify prostate tumors, saliva-based test for SARS-CoV-2, and more.